8-K: An Open Letter to the Cassava Community from Rick Barry
8-K: Notice of Pendency of Settlement
8-K: Cassava Sciences Announces Changes in Executive Leadership, Enhanced Corporate Governance and Other Initiatives
8-K: Cassava Sciences' Update on the Investigation of Dr Huaren Wang
8-K: Employment agreement amendment, dated May 20, 2024, by and between Cassava Sciences, Inc. and Eric J. Schoen
8-K: Poll Results of 2024 Stockholders Meeting
8-K: Cassava Sciences Reports Q1 2024 Financial Results and Clinical Updates on Phase 3 Trials of Simufilam
Cassava Sciences | 8-K: Cassava Sciences Announces Over $125 Million Raised from Warrant Distribution
8-K: Notice of Guaranteed Delivery for Exercise of Warrants of Cassava Sciences
Cassava Sciences | 8-K: Redemption Date Announced for Warrants
Cassava Sciences | DEF 14A: Definitive information statements
Cassava Sciences | 8-K: Cassava Sciences Reports Full-year 2023 Financial Results and Corporate Updates
Cassava Sciences | 8-K: No Decline in Cognition Scores in Patients with Mild Alzheimer's Disease Who Received Simufilam Continuously For 24 Months
Cassava Sciences | 8-K: Entry into Material Definitive Agreements
Cassava Sciences | 8-K: Current report
Cassava Sciences | 8-K: Current report
Cassava Sciences | 8-K: Cassava Sciences Reports Third Quarter 2023 Financial and Operating Results
Cassava Sciences | 8-K: Current report
Cassava Sciences | 8-K: Cassava Sciences Reports Q2 2023 Financial Results And Operating Updates
Cassava Sciences | 8-K: Oral Simufilam Slowed Cognitive Decline in a Randomized Withdrawal Trial of Mild-to-Moderate Alzheimer's Disease
No Data